After combination therapy, the SphK2-high activity group manifested significantly elevated T cell infiltration when compared to the SphK2-low group (Figure 5G), suggesting enhanced T cell-mediated anti-tumor immunity in the former group. The gene discussed is SPHK2; the disease is neoplasm.